Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?

Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, marking a 37.1% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.